Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial

Yan Zhao(Peking University), Bo Chen(Bioscience (China)), Bin Yang(Southern Medical University), Qingchun Diao(Beijing University of Chinese Medicine), Xiujuan Xia(Qingdao University), Xiaohua Tao(Zhejiang Provincial People's Hospital), Qianjin Lu(Central South University), Furen Zhang(Shandong Provincial Institute of Dermatology and Venereology), Fuqiu Li(Second Affiliated Hospital of Jilin University), Liming Wu(Hangzhou First People's Hospital), Xiao‐Yong Man(Second Affiliated Hospital of Zhejiang University), Linfeng Li(Beijing Tongren Hospital), Jianzhong Zhang(Chinese Academy of Sciences), Chunlei Zhang(Peking University), Yumei Li(Qingdao University), Jinyan Wang(Ningbo No. 2 Hospital), Hao Cheng(Sir Run Run Shaw Hospital), Yingmin Jia(Bioscience (China)), Guoqing Zhao(Jilin University), Xiaohong Zhu(Shanxi Medical University), Litao Zhang(Tianjin University of Traditional Chinese Medicine), Jianyun Lu(Central South University), Jingyi Li(Sichuan University), Jinchun Yan(Bioscience (China)), Yangfeng Ding(Shanghai Stomatological Hospital)
Chinese Medical Journal
July 21, 2023
Cited by 40


Related Papers